文献速递湿疹皮炎与荨麻疹

度普利尤单抗改善手足特应性皮炎体征、症状、生活质量和工作效率:3期随机双盲安慰剂对照试验结果

Dupilumab treatment improves signs, symptoms, quality of life, and work productivity in patients with atopic hand and foot dermatitis: Results from a phase 3, randomized, double-blind, placebo-controlled trial.
PubMed 文献 · J Am Acad Dermatol · 2024-02-01

这项多中心3期试验纳入133例中重度手足特应性皮炎患者,随机接受度普利尤单抗单药或安慰剂治疗16周。

要点

  • 度普利尤单抗单药治疗16周可显著改善手足特应性皮炎的疾病严重度。
  • 瘙痒、疼痛、生活质量、睡眠等预设次要终点均达到,安全性可接受。

核心结论

  • 度普利尤单抗单药治疗在手足特应性皮炎的多个领域带来显著改善,且安全性可接受,支持其作为这一难治情况的全身治疗选择。

研究设计与样本

  • 多中心3期随机双盲安慰剂对照试验,纳入成人及青少年中重度手足特应性皮炎患者,随机接受度普利尤单抗单药(获批用于泛发性特应性皮炎的方案)或匹配安慰剂。
  • 共133例患者(成人106例,青少年27例)随机分配至度普利尤单抗组(n=67)或安慰剂组(n=66)。

主要发现

  • 所有其他预设终点均达到,安全性与其他特应性皮炎患者中的已知度普利尤单抗特征一致。

关键数值与推荐

  • 主要终点:第16周达到手足研究者总体评估评分0或1的患者比例。

临床怎么用

  • 对于中重度手足特应性皮炎患者,度普利尤单抗单药可作为全身治疗选择,改善体征、症状、生活质量和工作效率。

局限性

  • 研究为短期16周治疗期。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite high disease burden, systemic treatment options for patients with atopic hand and/or foot dermatitis (H/F AD) are limited. OBJECTIVES: To evaluate efficacy and safety of dupilumab in H/F AD using specific instruments for assessing disease severity on hands and feet. METHODS: In this multicenter phase 3 trial, adults and adolescents with moderate-to-severe H/F AD were randomized to dupilumab monotherapy (regimen approved for generalized AD), or matched placebo. The primary endpoint was proportion of patients achieving Hand and Foot Investigator's Global Assessment score 0 or 1 at week 16. Secondary prespecified endpoints assessed the severity and extent of signs, symptom intensity (itch, pain), quality of life, and sleep. RESULTS: A total of 133 patients (adults = 106, adolescents = 27) were randomized to dupilumab (n = 67) or placebo (n = 66). At week 16, significantly more patients receiving dupilumab (n = 27) than placebo (n = 11) achieved Hand and Foot Investigator's Global Assessment score 0 or 1 (40.3% vs 16.7%; P = .003). All other prespecified endpoints were met. Safety was consistent with the known AD dupilumab profile. LIMITATIONS: Short-term, 16-week treatment period. CONCLUSION: Dupilumab monotherapy resulted in significant improvements across different domains of H/F AD with acceptable safety, supporting dupilumab as a systemic treatment approach for this often difficult to treat condition.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Simpson EL, Silverberg JI, Worm M, et al. Dupilumab treatment improves signs, symptoms, quality of life, and work productivity in patients with atopic hand and foot dermatitis: Results from a phase 3, randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2024. PMID: 38296199. doi:10.1016/j.jaad.2023.12.066

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。